Dual Mode Remote Ischemic Preconditioning Device
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing remote ischemic preconditioning devices have predetermined treatment protocols that may not adequately address the specific needs of patients with preexisting conditions such as advanced age or diabetes, leading to impaired activation of protective mechanisms against ischemia-reperfusion injury.
Innovation Solution
A dual-mode automatic remote ischemic preconditioning device that allows for patient-specific treatment protocols, with the option to increase the intensity of the ischemic stimulus based on preexisting conditions, using a controller to switch between initial and enhanced treatment protocols, and optionally utilizing tissue perfusion analysis for automatic mode selection.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If a predetermined treatment protocol is used for all patients, then the device is simple to operate, but it cannot adequately address the specific needs of patients with preexisting conditions
Solution Approach 1:
The device transitions from a static predetermined protocol to a dynamic dual-mode system that adapts treatment intensity based on patient characteristics. The controller can switch between initial and enhanced protocols, allowing the treatment parameters to change dynamically according to patient response and preexisting conditions.
Solution Approach 2:
The invention changes key treatment parameters including occlusion duration (5 minutes in initial mode, 10 minutes in enhanced mode), number of cycles (3-4 cycles initially, up to 6-8 cycles with enhancement), and cuff pressure levels. These parameter adjustments allow the same device to deliver both standard and intensified therapy.
2Reliability
If the intensity of ischemic stimulus is increased for patients with preexisting conditions, then protective mechanisms are adequately activated, but the treatment duration and complexity increase
Solution Approach 1:
The device performs preliminary assessment of patient characteristics (age, diabetes status, blood pressure) before or during treatment initiation. Based on this preliminary evaluation, it pre-determines whether to switch to the enhanced protocol, avoiding unnecessary treatment extensions for patients who respond adequately to the initial protocol.
Solution Approach 2:
The system incorporates feedback mechanisms to monitor patient response during treatment. If the initial protocol fails to adequately activate protective mechanisms (assessed through physiological parameters), the system triggers a switch to the enhanced protocol with increased intensity and duration.
3Adaptability or versatility
If manual assessment of patient conditions is performed, then treatment can be individualized, but the ease of operation decreases
Solution Approach 1:
The device performs self-assessment by automatically evaluating patient characteristics such as age, blood pressure, and diabetes status either through integrated sensors or operator input at initialization. The system then autonomously selects the appropriate treatment mode without requiring manual clinical assessment, making the device user-friendly while maintaining individualization.
Solution Approach 2:
The invention replaces manual clinical assessment (mechanical/procedural evaluation by healthcare providers) with automated electronic assessment systems. The controller automatically processes patient data and determines the appropriate protocol, substituting human judgment with algorithm-based decision-making.
Data Source
AI summary
A dual mode automatic device for delivery of remote ischemic preconditioning treatment includes a cuff and a controller configured to deliver a first regular treatment protocol or a second extended treatment protocol. Switching to an extended treatment protocol may be done by an operator for selected groups of patients such as elderly or patients with diabetes. Automatic determination of the best mode is also disclosed. Optimal delivery of remote ischemic preconditioning treatment in this individualized patient-specific manner provides strong ischemic protection to a greater number of patients.